Whalesbook
Valuation Concerns Mount
Prabhudas Lilladher's decision to lower Aurobindo Pharma's rating from 'Buy' to 'Hold' signals a shift in institutional sentiment toward the company's stock. Despite consistent EBITDA of around INR 18 billion in Q4FY26, the market is now more focused on whether the stock's current valuation is sustainable. Trading at a price-to-earnings multiple close to 18 times forward earnings, Aurobindo Pharma has seen significant gains over the past year, outpacing its peers. Analysts suggest that at its current price of approximately INR 1,460–1,470, the stock has largely factored in near-term growth prospects, limiting potential for further increases without new positive developments.
Regulatory Issues Cloud Operations
While Aurobindo Pharma is investing in growth areas like biosimilars and schemes supported by the Production Linked Incentive (PLI) program, regulatory challenges persist. On May 23, 2026, the company announced that the U.S. Food and Drug Administration (FDA) issued an 'Official Action Indicated' (OAI) classification for its Eugia Pharma Unit-I manufacturing facility in Telangana. This follows an inspection in February 2026, which resulted in four observations. Aurobindo Pharma's management has stated they do not expect immediate operational or financial impacts. However, this OAI status, similar to one received by the Rajasthan Unit-II earlier this year, indicates ongoing compliance issues across its manufacturing network. Investors worry that these recurring regulatory problems could delay the approval of pending drug applications in the United States.
Potential Risks Highlighted
Aurobindo Pharma operates in a sector where strict compliance is crucial. The Eugia subsidiary, central to the company's specialized formulations strategy, has become a frequent source of regulatory concern. In contrast to competitors like Sun Pharmaceutical, which have managed facility audits more effectively, Aurobindo's repeated OAI classifications may suggest underlying quality control challenges. The company's recent share buyback program, valued at INR 800 crore, is seen as a positive signal from management but may not be sufficient to offset significant capital expenditure requirements. If the issues at the Eugia facility are not resolved promptly, there is a risk of more serious regulatory actions, such as import bans or warning letters, which could significantly impact its U.S. revenues.
Mixed Outlook Ahead
The market outlook for Aurobindo Pharma remains divided. The current consensus target price of around INR 1,400 suggests that analysts anticipate a period of stock price stabilization. While the company is expected to benefit from growth in the vaccine and injectable markets from FY27 onward, its immediate performance will depend on resolving the observations at the Eugia facility. Institutional investors are likely to wait for clearer evidence of facility compliance and improved profit margins before increasing their positions.